AltruBio Inc.
AltruBio Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at AltruBio Inc..
AltruBio Inc. is a company.
Key people at AltruBio Inc..
Key people at AltruBio Inc..
AltruBio Inc. is a clinical-stage biotechnology company developing novel PSGL-1 agonist antibodies as immune checkpoint enhancers (ICEs) to treat immunological diseases with high unmet needs, such as ulcerative colitis (UC), psoriatic arthritis (PsA), psoriasis, and graft-versus-host disease (GVHD). Headquartered in San Francisco with an R&D lab in Taipei, Taiwan, the company targets chronically activated T-cells to restore immune homeostasis. Its lead candidates, ALTB-268 (Phase 1 completed in healthy volunteers, Phase 2a in UC initiated late 2023) and ALTB-168 (Phase 2 trials completed in psoriasis, PsA, and UC with clinical efficacy signals), offer higher potency and subcutaneous dosing potential.[1][2][4] Founded in 2020 as a privately funded entity, AltruBio raised a Series A in Q2 2021 and a landmark $225M Series B, advancing its pipeline toward multiple autoimmune indications.[1][3][4]
AltruBio, formerly AbGenomics Holding Inc., was established in 2020 in California, evolving from prior biotech efforts into a focused immunology player.[3] Under the leadership of President and CEO Judy Chou, PhD, who brings proven industry experience, the company emerged from unique insights into immune regulation, particularly PSGL-1 agonists discovered and developed in-house.[1][4] A pivotal "Cinderella story" unfolded as AltruBio navigated near-bankruptcy discussions to secure a transformative $225M Series B, fueling clinical milestones like ALTB-268's Phase 1 completion and Phase 2a start.[4] Early traction included Series A funding in 2021 and clinician-proven mechanisms across four diseases, setting the stage for broader pipeline expansion.[1]
AltruBio stands out in biotech through its proprietary platform and execution:
AltruBio rides the explosive growth in autoimmune and immunology therapeutics, fueled by advances in immune checkpoint modulation beyond oncology (e.g., PD-1 analogs now targeting inflammation).[1][2] Timing aligns with surging demand for durable, safer treatments amid rising autoimmune prevalence—UC, PsA, and psoriasis affect millions with limited options—bolstered by market forces like biologics competition and post-pandemic inflammation focus.[1][4] By validating PSGL-1 agonists clinically, AltruBio influences the ecosystem, offering a scalable platform that could expand to other T-cell driven diseases, challenging incumbents and attracting partnerships (seeking for two unlicensed products).[1] Its cross-Pacific model exemplifies biotech globalization, enhancing U.S.-Asia innovation hubs.
AltruBio's trajectory points to Phase 2b/3 readouts for ALTB-268 in UC and beyond, with potential GVHD expansion and new preclinical data (e.g., FOCIS 2025 T-cell models) de-risking the platform.[4] Trends like AI-driven immunology discovery and combo therapies will amplify its edge, while Series B capital supports milestones through 2026+. Influence may grow via partnerships or acquisitions, cementing it as a leader in next-gen immune modulators—transforming its bankruptcy scare into a blueprint for resilient biotech innovation, much like its opening promise of safer patient therapies.[1][4]
